ICI 35 868 or propofol resulted from research into the anaesthetic activity of hindered phenols at the ICI laboratories (now Astra Zeneca) in Macclesfield, Cheshire. These compounds exist as oils at room temperature but can be administered intravenously in aqueous solution with the solubilizing agent Cremophor EL. Of all the compounds studied, only ICI 35 868 was found to have desirable properties in animals. Further studies were then conducted by Glen and his colleagues to investigate this agent and compare it with other intravenous anaesthetic agents.
Initial studies were conducted to determine the ideal concentration and solution. The active agent is 2,6-diisopropyl phenol, a chemical unrelated to any previous anaesthetic agents. The first formulations were 2% solutions with 16% Cremophor EL and 8.66% ethyl alcohol. Varying the Cremophor EL between 5 and 20% made no difference and the ethyl alcohol was found to have no beneficial effects.
In a wide range of animal species, ICI 35 868 was found to have similar effects to thiopentone, Single doses produced anaesthesia with rapid onset, short duration and no excitatory side-effects. It was also found to have hypotensive effects similar to thiopentone but was 1.8 times more potent. The most encouraging findings were that repeated doses could be given without significantly prolonging the recovery time, time to complete recovery was faster and no tissue damage was observed with intra-arterial injection.
Preliminary studies in man were undertaken by Kay and Rolly in Belgium and their findings confirmed these early animal studies. The principal side-effect that they noticed was pain on injection, something that could not be concluded from animal studies. Initially it was thought that this was most likely due to the Cremophor EL. Cremophor EL was also suspected as a cause of anaphylaxis and was not an ideal solvent. These initial results led Glen to conclude that "Should further work in man confirm that ICI 35 868 has a desirable anaesthetic profile, it is hoped that an alternative formulation can be developed which would be more acceptable for wider clinical use."
Meanwhile ICI supplied the drug for further research as a 1% aqueous solution in Cremophor EL with the trade name Diprivan. In 1981 Briggs and colleagues studied Diprivan in healthy women undergoing minor gynaecological procedures. Their aims were to assess the optimal induction dose and its local and general sideeffects over a range of doses. They found that at 1.75 mg/kg, not all patients were anaesthetized but that 2 mg/kg seemed a satisfactory dose in all patients. Involuntary movements, hiccoughing or coughing were rare in any of the patients but hypotension and respiratory depression were dose related. Pain on injection was greater in the smaller veins on the back of the hand but uncommon in the antecubital fossa. All patients recovered rapidly and none reported postoperative nausea or vomiting. One patient suffered an allergic reaction characterized by hypotension, cough and bronchospasm. Their conclusions were similar to those of the laboratory researchers "... it is therefore highly desirable to find another solubilizing agent. The reaction encountered was not dangerous and resembles those seen with Althesin, but further reactions are to be anticipated. Since di-isopropyl phenol rather than the Cremophor EL is likely to cause pain on injection, this pain may remain as an undesirable feature, but it is brief in duration, whereas the hypersensitivity reactions are potentially lifethreatening." These conclusions were sufficient for trials on Diprivan to cease until another solvent could be found.
In 1984, Glen described his research into an emulsion formulation of IC 35 868. The formulation consisted of a 1% aqueous emulsion containing 10% soya bean oil, 1.2% egg phosphatide and 2.25% glycerol which was compared with a 1% solubilized formulation containing 16% Cremophor EL. Initial results suggested that recovery time was slightly longer with the emulsion. This was attributed to the greater amount of soya bean oil and a larger particle size. Both of these factors led to an increase in the active drug being retained in the oil phase of the emulsion. There was a slight decrease in activity with the emulsion formulation in mice and various animal models confirmed that the emulsion did not appear to cause histamine release. In contrast, the Cremophor solution caused histamine release in 100% of some animal models. Glen's conclusion at this stage was "While the results of the present studies suggest that the emulsion formulation of ICI 35 868 should have advantages over the Cremophor formulation, this will not be confirmed until extensive clinical experience has been gained with this new formulation."
Many clinical trials in Britain confirmed these laboratory findings. Propofol was released for general use in Europe in the late 1980s and was approved for use by the Food and Drug Administration in the United States in 1989. A review by Peter Sebel in Anesthesiology at this time predicted " Propofol is unlikely to supplant thiopental in routine practice. It is however, likely to be extensively used for day-stay anesthesia, ophthalmic surgery (because of its beneficial effects on IOP), and sedation, both preoperatively and in the ICU. Its use by continuous infusion for maintenance of anaesthesia will increase with the development of more sophisticated administration devices."
Initially the cost of propofol limited its use to short stay surgery. When the laryngeal mask was released in the early 1990s, clinicians rapidly discovered that propofol provided the best conditions for insertion. Propofol probably aided the acceptance of the laryngeal mask and vice versa. As Sebel predicted, propofol infusions have become popular for total intravenous anaesthesia. In 1986, Astra Zeneca released the "Diprifusor", a target-controlled infusion device which allows propofol to be delivered to a steady state blood concentration. It remains to be seen whether the improvement in drugs and technology will lead to a greater acceptance of total intravenous anaesthesia.
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